Mirati Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities:
Net loss
Non-cash adjustments reconciling net loss to operating cash flows
Non-cash consideration earned from license agreement
Change in fair value of long-term investment
Depreciation of property and equipment
Depreciation and amortization expense
Amortization of premium and accretion of discounts on investments
Share-based compensation expense
Loss on disposal of fixed assets
Foreign currency adjustments
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Other current assets
Other long-term assets
Right-of-use asset
Lease liability
Accounts payable, accrued liabilities and other liabilities
Cash flows used in operating activities
Investing activities:
Purchases of short-term investments
Sales and maturities of short-term investments
Purchases of property and equipment
Cash flows provided by (used in) investing activities
Financing activities:
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of common stock under equity incentive plans
Proceeds from disgorgement of shareholders’ short-swing profits
Proceeds from issuances under employee stock purchase plan
Cash flows provided by financing activities
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents
(Decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of year
Cash, cash equivalents and restricted cash, end of year
Supplemental disclosures of non-cash investing activities:
Accrued capital expenditures
Capitalized intangible asset included in accrued liabilities
Allowance utilized for tenant improvements
Initial recognition of operating right-of-use asset
Initial recognition of operating lease liability
Reconciliation of cash, cash equivalents and restricted cash, end of year:
Cash and cash equivalents
Restricted cash included in other long-term assets

Comments